AEON Biopharma, Inc.
AEONAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Lake Street | maintain | Buy | Oct 1, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 14, 2026 |
| Aegis Capital | maintain | Buy | Oct 8, 2025 |
| HC Wainwright & Co. | maintain | Buy | Oct 1, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jul 10, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 30, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 6, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 17, 2024 |
Earnings History
Next report: Nov 13, 2026 · EPS est. $-0.10| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-0.02 | $-0.23 | — | — |
| May 14, 2026 | $-0.44 | $-0.44 | — | — |
| Mar 30, 2026 | $-5.24 | $-0.17 | — | — |
| Nov 14, 2025 | $-0.39 | $-0.43 | — | — |
| Aug 11, 2025 | $-0.60 | $-11.51 | — | — |
| May 14, 2025 | $2.28 | $-13.67 | — | — |
| Mar 24, 2025 | $3.75 | $-12.95 | — | — |
| Nov 13, 2024 | $-11.51 | $-11.51 | — | — |
News
TORONTO, ONTARIO – TheNewswire - October 27, 2026 — AEON STRATEGIES LTD. (formerly Cloud3 Ventures Inc.) (CSE: AEON) (OTCQB: CLDVF) (FSE: WQ40) (the “ Company ” or “ Aeon ”) provides an update to its news release dated October 23, 2026 (the “ Default Announcement ”) regarding the anticipated late filing of its audited annual financial statements for the year ended June 30, 2026, the related management's discussion and analysis and the related CEO and CFO certifications (collectively, the “ Annua…
TORONTO, ONTARIO – TheNewswire - October 23, 202 6 - AEON STRATEGIES LTD. (formerly Cloud3 Ventures Inc.) (CSE: AEON) (OTCQB:CLDVF)(FSE:WQ40) (the “ Company ” or “ Aeon ”) announces that it expects to be unable to file its audited annual financial statements for the year ended June 30, 2026, the related management's discussion and analysis and the related CEO and CFO certifications (collectively, the “ Annual Filings ”) by the October 28, 2026 filing deadline under Part 4 of National Instrument …
FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX® may be submitted as supportive evidence; AEON expects to advance the required scientific bridging work AEON plans to submit an IND for CMAP pharmacodynamic study in the fourth quarter of 2026 AEON plans to leverage its analytical, pharmacodynamic, and existing comparative human evidence to support a potential streamlined development path ALISO VIEJO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEO…
ABP-450 and BOTOX® demonstrated comparable rates of potency loss under thermal stress and similar site-specific oxidation patterns across methionine sites evaluated Results provide additional analytical evidence supporting comparability and establish the basis for AEON's planned multi-lot comparability study ALISO VIEJO, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to…
ALISO VIEJO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, announced today that AEON management will host in-person 1x1 investor meetings at Lake Street Capital Markets' 10th Annual Best Ideas Growth (BIG10) Conference being held in New York City on Thursday, September 10th, 2026…
- Former Deputy Director of the FDA's Office of Neuroscience - Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the regulatory strategy for ABP-450 ALISO VIEJO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry,…
- Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed
- Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450's development program